Calls
1
u/Efficient-Two-5030
Reddit r/biotech_stocks
Win Rate
0.0%
return
-1.9%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 12
$4.74
-1.9%
The author is bullish on AQST, mapping a sequence of regulatory and commercial catalysts to escalating price levels. Anaphylm resubmission acceptance (late Q3/early Q4 '26) is seen driving $5.50-$6.00, FDA filing and clock-setting pushing $6.50-$7.25, and eventual Anaphylm US approval in '27 reaching $12-$16. Further catalysts include Canada NDS filing, Libervant US deal or solo launch, age-expansion PR, EU MAA filing, and AQST-108 data, with the author expecting high-teens to $20s on 7-product royalties and insurance uptake. Main risk is that these are speculative targets dependent on regulatory and commercial execution.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Efficient-Two-5030 has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: AQST.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
